This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Treatment of Insomnia in Migraineurs

This study has been completed.
Sponsor:
Collaborator:
Sepracor Incorporated, 84 Waterford Drive, Marlborough, MA 01752
Information provided by:
MedVadis Research Corporation
ClinicalTrials.gov Identifier:
NCT00812214
First received: December 18, 2008
Last updated: December 19, 2008
Last verified: December 2008
  Purpose
It is hypothesized that treating insomnia in migraineurs, many of whom also have tension headaches, prolongs total sleep time to the extent that it decreases overall headache frequency. Chronic headache sufferers also feel more tired during the day2, undoubtedly affecting daytime functioning, which is hypothesized to improve as well with prolonged total sleep time.

Condition Intervention Phase
Insomnia Migraine Drug: eszopiclone Drug: placebo Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Official Title: Treatment of Insomnia in Migraineurs With Eszopiclone (Lunesta™) and Its Effect on Sleep Time, Headache Frequency, and Daytime Functioning: a Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Pilot Study

Resource links provided by NLM:


Further study details as provided by MedVadis Research Corporation:

Primary Outcome Measures:
  • Total sleep time [ Time Frame: 6 weeks ]

Secondary Outcome Measures:
  • headache days [ Time Frame: 6 weeks ]

Enrollment: 113
Study Start Date: April 2007
Study Completion Date: September 2008
Primary Completion Date: September 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: eszopiclone
3 mg qhs
Placebo Comparator: 2 Drug: placebo

Detailed Description:
The objective of the study is to determine the effect of prolonging total sleep time in migraineurs with insomnia on overall headache frequency, daytime alertness, fatigue, and functioning. The prolongation of total sleep time is accomplished by bedtime administration of 3 mg eszopiclone (Lunesta™), compared with placebo through a parallel-group design.
  Eligibility

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
Subjects included in the study are men and women, 18 to 64 years of age (inclusive), with IHS-II migraine with/without aura and DSM-IV primary insomnia (sleep onset/sleep maintenance). The required migraine frequency is 4-12 times per month, with a maximum of 20 days with headache per month, for 1 month or longer prior to screening. The requirement with regard to insomnia is a usual, estimated total sleep time of 6½ hours per night or less, for 1 month or longer prior to screening, due to problems falling asleep, waking up during the night, or waking up early. The sleep and headache eligibility criteria are confirmed at the randomization visit on the basis of the daily diary.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00812214

Sponsors and Collaborators
MedVadis Research Corporation
Sepracor Incorporated, 84 Waterford Drive, Marlborough, MA 01752
Investigators
Principal Investigator: Egilius L.H. Spierings, M.D., Ph.D. MedVadis Research Corporation
  More Information

Responsible Party: Egilius L.H. Spierings, M.D., Ph.D., Medvadis Research Corporation
ClinicalTrials.gov Identifier: NCT00812214     History of Changes
Other Study ID Numbers: ESRC024
Study First Received: December 18, 2008
Last Updated: December 19, 2008

Keywords provided by MedVadis Research Corporation:
insomnia
migraine
eszopiclone
insomnia in migraineurs

Additional relevant MeSH terms:
Migraine Disorders
Sleep Initiation and Maintenance Disorders
Headache Disorders, Primary
Headache Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Sleep Disorders, Intrinsic
Dyssomnias
Sleep Wake Disorders
Mental Disorders
Eszopiclone
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on June 27, 2017